共表达IL-7和CCL19的VSVΔ51溶瘤病毒在肝癌中的抗肿瘤活性研究-东南大学学报医学版

共表达IL-7和CCL19的VSVΔ51溶瘤病毒在肝癌中的抗肿瘤活性研究

单位：1. 河北省邯郸市中心医院肿瘤三科, 河北邯郸 056000;
2. 河北省邯郸市传染病医院肝四科, 河北邯郸 056000

分类号：R735.7

出版年·卷·期（页码）：2023·42·第四期（526-532）

摘要：

目的:构建共表达白细胞介素7(interleukin-7,IL-7)和趋化因子配体19[chemokine(C-C motif) ligand 19,CCL19]的溶瘤病毒VSVΔ51(7×19 VSVΔ51),并探索其在肝癌中的抗肿瘤活性。方法:细胞的活力测定(MTS法)检测溶瘤病毒对肿瘤细胞的细胞毒性;ELISA法检测病毒感染上清及肿瘤组织匀浆中的IL-7和CCL19的含量;皮下移植瘤模型检测溶瘤病毒的肿瘤抑制能力;流式细胞术检测肿瘤浸润T细胞的表型;免疫组化法检测肿瘤浸润T细胞及IFN-γ的含量。结果:VSVΔ51和7×19 VSVΔ51病毒均可以在小鼠肝癌细胞H22和Hepa1-6中复制,在2 PFU时裂解细胞的效率接近100%;VSVΔ51和7×19 VSVΔ51病毒均对小鼠肝癌移植瘤的生长产生抑制作用,且7×19 VSVΔ51病毒较VSVΔ51病毒抑制能力更强[瘤质量(232.7±13.72) mg vs.(603.8±20.3) mg,P＜0.000 1];7×19 VSVΔ51病毒组治疗后肿瘤组织中IL-7[(673.5±62.6)pg·ml^-1 vs.(383.1±108.3) pg·ml^-1,P＜0.01]和CCL19[(756.2±41.6)pg·ml^-1 vs.(356.2±50.2) pg·ml^-1,P＜0.001]的含量较VSVΔ51病毒组显著升高,肿瘤浸润T细胞的数目增多(805±133 vs. 392±21,P＜0.05),干细胞样记忆T细胞的比例显著提升[(72.5±9.8)% vs. (49.3±8.5)%,P＜0.001)],肿瘤组织中IFN-γ的含量也明显升高[(817±52) pg·ml^-1 vs. (227±63) pg·ml^-1,P＜0.001)]。结论:7×19 VSVΔ51病毒可在肝癌小鼠模型中激发出强大的抗肿瘤免疫反应并发挥显著的抗肿瘤作用。

Objective: To construct an oncolytic virus VSVΔ51 overexpressing IL-7 and CCL19(7×19 VSVΔ51), and to explore its antitumor activity in hepatocellular carcinoma. Methods: MTS assay was used to detect the cytotoxicity of oncolytic virus on tumor cells. The contents of IL-7 and CCL19 in cell supernatant after viral infection and tumor tissue homogenate were detected by ELISA. Subcutaneous tumor transplantation model were used to verify the tumor suppressive ability of oncolytic virus. The phenotype of tumor infiltrating T cells was detected by flow cytometry. The contents of T cells and IFN-γ were detected by immunohistochemistry. Results: Both VSVΔ51 and 7×19 VSVΔ51 could replicate and lyse tumor cells in mouse hepatoma cells H22 and Hepa1-6. Both VSVΔ51 and 7×19 VSVΔ51 could inhibit the growth of hepatocellular carcinoma xenografts in mice, but 7×19 VSVΔ51 had a stronger inhibitory effect than VSVΔ51 [tumor weight(232.7±13.72) mg vs.(603.8±20.3) mg,P＜0.000 1]. After 7×19 VSVΔ51 treatment, the contents of IL-7[(673.5±62.6)pg·ml^-1 vs.(383.1±108.3) pg·ml^-1,P＜0.01] and CCL19 [(756.2±41.6)pg·ml^-1 vs.(356.2±50.2) pg·ml^-1,P＜0.001] in tumor tissues were significantly higher than those in VSVΔ51 group, the number of tumors infiltrating T cells was increased(805±133 vs. 392±21,P＜0.05), the proportion of stem cell-like memory T cells was significantly increased[(72.5±9.8)% vs. (49.3±8.5)%,P＜0.001)], and the content of IFN-γ in tumor tissues was also significantly increased[(817±52)pg·ml^-1 vs. (227±63) pg·ml^-1,P＜0.001)]. Conclusion: 7×19 VSVΔ51 could stimulate a strong antitumor immune response and play a significant antitumor effect in the hepatocellular carcinoma xenografts model.

参考文献：

[1] LO DICO R,FARON M,YONEMURA Y,et al.Combined liver resection and cytoreductive surgery with HIPEC for metastatic colorectal cancer:results of a worldwide analysis of 565 patients from the Peritoneal Surface Oncology Group International(PSOGI)[J].Eur J Surg Oncol,2021,47(1):89-100.
[2] 蔡宇,罗利琼.靶向谷氨酰胺和PD1抑制剂在肝癌中的研究进展[J].现代医学,2022,50(8):1077-1081.
[3] MAUCORT-BOULCH D,DE MARTEL C,FRANCESCHI S,et al.Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide[J].Int J Cancer,2018,142(12):2471-2477.
[4] ABDEL-RAHMAN O.A real-world,population-based study for the outcomes of patients with metastatic colorectal cancer to the liver with distant lymph node metastases treated with metastasectomy[J].J Comp Eff Res,2022,11(4):243-250.
[5] VALERY P C,LAVERSANNE M,CLARK P J,et al.Projections of primary liver cancer to 2030 in 30 countries worldwide[J].Hepatology,2018,67(2):600-611.
[6] SAKUDA T,KUBO T,JOHAN M P,et al.Development of an oncolytic recombinant vesicular stomatitis virus encoding a tumor-suppressor microRNA[J].Anticancer Res,2020,40(11):6319-6325.
[7] NAKATAKE M,KUWANO N,KAITSURUMARU E,et al.Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment[J].Mol Ther,2021,29(5):1782-1793.
[8] RIDER P J F,UCHE I K,SWEENY L,et al.Anti-viral immunity in the tumor microenvironment:implications for the rational design of herpes simplex virus type 1 oncolytic virotherapy[J].Curr Clin Microbiol Rep,2019,6(4):193-199.
[9] 刘东涛,马俊文,丁波,等.表达CD40配体的溶瘤痘苗病毒(CD40L-VV)抑制结直肠癌细胞生长并增强荷瘤小鼠T细胞抗肿瘤活性[J].细胞与分子免疫学杂志,2021,37(7):602-607.
[10] JIN J,WANG R,YANG J,et al.Bispecific antibody expressed by an oncolytic herpes simplex virus type 2 can transform heterologous T cells into uniform tumor killer cells[J].Hum Gene Ther,2022,33(11-12):649-663.
[11] BEUG S T,PICHETTE S J,ST-JEAN M,et al.Combination of IAP antagonists and TNF-alpha-armed oncolytic viruses induce tumor vascular shutdown and tumor regression[J].Mol Ther Oncolytics,2018,10:28-39.
[12] ALAJEZ N M,MOCANU J D,SHI W,et al.Efficacy of systemically administered mutant vesicular stomatitis virus(VSVDelta51) combined with radiation for nasopharyngeal carcinoma[J].Clin Cancer Res,2008,14(15):4891-4897.
[13] ALAJEZ N M,MOCANU J D,KRUSHEL T,et al.Enhanced vesicular stomatitis virus(VSVDelta51) targeting of head and neck cancer in combination with radiation therapy or ZD6126 vascular disrupting agent[J].Cancer Cell Int,2012,12(1):27.
[14] LINK A,VOGT T K,FAVRE S,et al.Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells[J].Nat Immunol,2007,8(11):1255-1265.
[15] JIANG J,WANG W,XIANG W,et al.The phosphoinositide 3-kinase inhibitor ZSTK474 increases the susceptibility of osteosarcoma cells to oncolytic vesicular stomatitis virus VSVDelta51 via aggravating endoplasmic reticulum stress[J].Bioengineered,2021,12(2):11847-11857.
[16] LUTHER S A,BIDGOL A,HARGREAVES D C,et al.Differing activities of homeostatic chemokines CCL19,CCL21,and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis[J].J Immunol,2002,169(1):424-433.
[17] ADACHI K,KANO Y,NAGAI T,et al.IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor[J].Nat Biotechnol,2018,36(4):346-351.
[18] ZHANG Y,LI B,BAI Q,et al.The lncRNA Snhg1-Vps13D vesicle trafficking system promotes memory CD8 T cell establishment via regulating the dual effects of IL-7 signaling[J].Signal Transduct Target Ther,2021,6(1):126.
[19] WEI J,ISHIZUKA J J.Going viral:HBV-specific CD8(+) tissue-resident memory T cells propagate anti-tumor immunity[J].Immunity,2021,54(8):1630-1632.
[20] ATASHEVA S,SHAYAKHMETOV D M.Oncolytic viruses for systemic administration:engineering a whole different animal[J].Mol Ther,2021,29(3):904-907.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录